<DOC>
	<DOCNO>NCT00749879</DOCNO>
	<brief_summary>This study intend evaluate pharmacokinetic property two dos ( 25 mg 50 mg ) Proellex® formulate microcrystalline cellulose ( MCC ) 2 different supplier feed fast state .</brief_summary>
	<brief_title>Crossover Study Safety PK Properties Proellex®</brief_title>
	<detailed_description />
	<criteria>Subject must able speak , read , understand English willing able provide write informed consent English Institutional Review Board ( IRB ) Premenopausal woman age 1834 , inclusive , body mass index 18 35 , inclusive Women childbearing potential must willing use effective nonhormonal , doublebarrier method contraception study period minimum 30 day discontinuation study medication . Women hysterectomy allow study Must negative urine pregnancy test screen Able swallow gelatin capsule Medically normal subject significant abnormal finding screen physical examination evaluate Principal Investigator would interfere subject participate study Must agree attempt become pregnant time study participation 30 day thereafter Other inclusion criterion may apply Symptomatic uterine fibroid endometriosis Past present history significant cardiovascular , renal , hepatic disease require ongoing medical therapy clinical intervention Past present history thrombophlebitis , thromboembolic disorder , cerebrovascular accident Abnormal screen visit vital sign clinical laboratory evaluation consider clinically significant Principal Investigator Significant organ abnormality disease ( base Principal Investigator 's judgment ) would opinion Principal Investigator exclude subject participate Other exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PK</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>